Hepatitis C in the rituximab era

Research output: Contribution to journalComment/debate

9 Scopus citations

Abstract

In a multicenter Japanese study, Ennishi et al have demonstrated both the benefits and the risks of adding rituximab to CHOP chemotherapy (R-CHOP) in patients with diffuse large B-cell lymphoma (DLBCL) and hepatitis C virus (HCV) infection.

Original languageEnglish (US)
Pages (from-to)5081-5082
Number of pages2
JournalBlood
Volume116
Issue number24
DOIs
StatePublished - Dec 9 2010

    Fingerprint

ASJC Scopus subject areas

  • Biochemistry
  • Immunology
  • Hematology
  • Cell Biology

Cite this